Two Clinical Trials Identify a Better Way to Target Appropriate Antibiotics for Patients Hospitalized With Pneumonia or Urinary Tract Infection

Business Wire04-19

Algorithm driven alerts help identify best antibiotic for patients with common infections in two 59-hospital trials, with implications to reduce antibiotic resistance NASHVILLE, Tenn. & ORANGE, Calif....

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2428654986?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/gHD2cpMTA03HeAgzGy0aeg--~B/aD0yMDU7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/ca827ce8b3198c61ca3294065bfcdbba","is_english":true,"pubTime":"2024-04-19 21:30","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2428654986","market":"us","top_or_hot":-1,"title":"Two Clinical Trials Identify a Better Way to Target Appropriate Antibiotics for Patients Hospitalized With Pneumonia or Urinary Tract Infection","media":"Business Wire","content":"<div>\n<p>Algorithm driven alerts help identify best antibiotic for patients with common infections in two 59-hospital trials, with implications to reduce antibiotic resistance\nNASHVILLE, Tenn. & ORANGE, Calif....</p>\n\n<a href=\"https://finance.yahoo.com/news/two-clinical-trials-identify-better-133000033.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Two Clinical Trials Identify a Better Way to Target Appropriate Antibiotics for Patients Hospitalized With Pneumonia or Urinary Tract Infection</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTwo Clinical Trials Identify a Better Way to Target Appropriate Antibiotics for Patients Hospitalized With Pneumonia or Urinary Tract Infection\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-19 21:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/two-clinical-trials-identify-better-133000033.html><strong>Business Wire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Algorithm driven alerts help identify best antibiotic for patients with common infections in two 59-hospital trials, with implications to reduce antibiotic resistance\nNASHVILLE, Tenn. & ORANGE, Calif....</p>\n\n<a href=\"https://finance.yahoo.com/news/two-clinical-trials-identify-better-133000033.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0868494617.USD","symbol_name":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","start_time":0,"source_url":"https://finance.yahoo.com/news/two-clinical-trials-identify-better-133000033.html","article_id":"2428654986","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/gHD2cpMTA03HeAgzGy0aeg--~B/aD0yMDU7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/ca827ce8b3198c61ca3294065bfcdbba"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2428654986","pubTimestamp":1713533400,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Algorithm driven alerts help identify best antibiotic for patients with common infections in two 59-hospital trials, with implications to reduce antibiotic resistance. NASHVILLE, Tenn. & ORANGE, Calif. & ATLANTA & BOSTON, April 19, 2024----Two large multi-state studies uncovered a highly effective way to improve antibiotic selection for patients hospitalized with pneumonia or urinary tract infections , enabling better antibiotic stewardship in hospitals, according to research studies published today in the Journal of the American Medical Association .Stewardship Prompts to Improve Antibiotic Selection for Pneumonia Stewardship Prompts to Improve Antibiotic Selection for Urinary Tract Infection. Physicians often choose extended-spectrum antibiotics that cover a very broad range of bacteria out of concern that their patients could be sick with antibiotic-resistant","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0648001328.SGD":"Natixis Harris Associates US Equity RA SGD","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","LU1267930490.SGD":"TEMPLETON GLOBAL EQUITY INCOME \"AS\" (SGD) INC A","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","LU0985489474.SGD":"First Eagle Amundi International AHS-C SGD-H","LU0882574055.USD":"富达全球健康医疗A ACC","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","LU0878866978.SGD":"First Eagle Amundi International AHS-QD SGD-H","BK4504":"桥水持仓","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","LU1201861249.SGD":"Natixis Harris Associates US Equity PA SGD-H","LU0211328371.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (MDIS) (USD)   INC","HCA":"HCA控股","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","LU0433182093.SGD":"First Eagle Amundi International AS-C SGD","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","IE00B775SV38.USD":"NEUBERGER BERMAN US MULTICAP OPPORTUNITIES \"A\" (USD) ACC","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","IE00B3S45H60.SGD":"Neuberger Berman US Multicap Opportunities A Acc SGD-H","BK4185":"保健护理机构","LU0068578508.USD":"First Eagle Amundi International Cl AU-C USD","LU0823411888.USD":"法巴消费创新基金 Cap","LU0052756011.USD":"TEMPLETON GLOBAL BALANCED \"A\" (USD) INC","BK4532":"文艺复兴科技持仓","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","BK4204":"教育服务","CDC":"VictoryShares US EQ Income Enhanced Volatility Wtd ETF","LU1267930227.SGD":"TEMPLETON GLOBAL BALANCED \"AS\" (SGD) ACC A","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","BK4585":"ETF&股票定投概念","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","LU1261432733.SGD":"Fidelity World A-ACC-SGD","BK4588":"碎股","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","BK4533":"AQR资本管理(全球第二大对冲基金)","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","LU0128525689.USD":"TEMPLETON GLOBAL BALANCED \"A\"(USD) ACC","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","LU0310800965.SGD":"FTIF - Templeton Global Balanced A Acc SGD","BK4114":"综合货品商店","TGT":"塔吉特","LU1489326972.SGD":"First Eagle Amundi International AHS-MD SGD-H","LU0130102774.USD":"Natixis Harris Associates US Equity RA USD","UTI":"环球技术学院"},"translate_title":"两项临床试验确定了针对肺炎或尿路感染住院患者的合适抗生素的更好方法","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"UTI":1,"TGT":1,"CDC":1,"HCA":0.9},"content_text":"Algorithm driven alerts help identify best antibiotic for patients with common infections in two 59-hospital trials, with implications to reduce antibiotic resistance\nNASHVILLE, Tenn. & ORANGE, Calif. & ATLANTA & BOSTON, April 19, 2024--(BUSINESS WIRE)--Two large multi-state studies uncovered a highly effective way to improve antibiotic selection for patients hospitalized with pneumonia or urinary tract infections (UTI), enabling better antibiotic stewardship in hospitals, according to research studies published today in the Journal of the American Medical Association (JAMA).\nStewardship Prompts to Improve Antibiotic Selection for Pneumonia Stewardship Prompts to Improve Antibiotic Selection for Urinary Tract Infection\nThe studies, led by Harvard Pilgrim Health Care Institute, HCA Healthcare and the University of California, Irvine, were funded by the Centers for Disease Control and Prevention (CDC).\nAntibiotic resistance, which occurs when germs like bacteria and fungi mutate to defeat the drugs designed to kill them, is a major public health threat. Helping clinicians tailor antibiotic prescriptions to individual patients can improve patient outcomes by preserving healthy bacteria in the body and reducing the risk of future antibiotic resistance. The two newly published studies, the INSPIRE Pneumonia and UTI Trials, involved more than 220,000 patients with pneumonia or UTI in 59 HCA Healthcare hospitals. In half of the hospitals, clinicians were given algorithm driven computerized alerts with information about the best antibiotic match for an individual patient at the moment antibiotics were being prescribed. This resulted in a better match for 28% of pneumonia patients and 17% of patients with UTI when compared to hospitals where physicians were not provided with alerts according to the trials.\nThe alerts used patient characteristics from the electronic medical record as well as hospital and location-specific data to determine the patient’s risk for an antibiotic-resistant infection. Assessment of risk was based on pre-trial data from more than 200,000 HCA Healthcare patients with pneumonia and UTI. Physicians treating patients with a low risk for antibiotic-resistant bacteria were prompted to give standard-spectrum antibiotics.\n\"Pneumonia and urinary tract infections are two of the most common infections requiring hospitalization and a major reason for overuse of broad-spectrum antibiotics,\" said Sujan Reddy, MD, Medical Officer in the Epidemiology, Research and Innovations Branch of CDC’s Division of Healthcare Quality Promotion. \"The INSPIRE trials have found a highly effective way to help physicians follow treatment recommendations to optimize antibiotic selection for each patient. These trials show the value of harnessing electronic health data to improve best practice.\"\nPhysicians often choose extended-spectrum antibiotics that cover a very broad range of bacteria out of concern that their patients could be sick with antibiotic-resistant bacteria. The INSPIRE trials identified patients with low risk for antibiotic resistance and prompted physicians to order standard-spectrum antibiotics if extended-spectrum antibiotics were being ordered. The trials found that giving physicians real-time information about their patients’ risk for antibiotic resistance worked significantly better to align antibiotic prescribing with current Infectious Diseases Society of America treatment recommendations.\n\"The right information at the right time can improve physician antibiotic selection,\" said Shruti Gohil, MD, MPH, Assistant Professor in the Division of Infectious Diseases at the University of California, Irvine School of Medicine. \"Many different bacteria can cause pneumonia or UTI, and picking the best matched antibiotic can be a challenge. Results from these trials show that giving physicians an alert informing them of their patient’s actual risk for antibiotic resistance can help them choose the best antibiotic and reduce extended-spectrum antibiotic use.\"\nThe INSPIRE trials were ongoing when the COVID-19 pandemic began. The trials showed continued beneficial effects in antibiotic selection when other hospitals in the nation were reporting large increases in use of extended-spectrum antibiotics. Part of this benefit is attributed to having an automated prompt that continues to work when hospital resources and staff attention are diverted.\nThe 59 participating community hospitals spanned 12 states and are part of HCA Healthcare, the largest private inpatient healthcare system in the U.S. The size of the studies involving a wide breadth of community hospitals supports the likelihood that results are applicable to hospitals across the country.\n\"HCA Healthcare is committed to excellence and innovation in delivering high-quality healthcare, and we are honored to continue our longstanding collaboration with the CDC, Harvard and UCI to leverage our health system’s scale to answer clinical questions for the benefit of patients,\" said Kenneth Sands, MD, MPH, chief epidemiologist at HCA Healthcare. \"We began using this groundbreaking technology and workflow in the hospitals where we tested it, and have since implemented it across our entire system to improve care for individual patients while also contributing to our growing body of work supporting appropriate antibiotic use everywhere.\"\nThe studies were conducted through a scientific consortium including HCA Healthcare, Harvard Medical School’s Department of Population Medicine at the Harvard Pilgrim Health Care Institute, the University of California, Irvine and the Centers for Disease Control and Prevention.\nAdditional information about the INSPIRE Pneumonia and UTI Trials can be found in the following JAMA author interview podcast.\nEditorial: Harnessing the Electronic Health Record to Improve Empiric Antibiotic Prescribing Author Interview Podcast\nAbout Centers for Disease Control and Prevention\nWhether diseases start at home or abroad, are curable or preventable, chronic or acute, or from human activity or deliberate attack, CDC’s world-leading experts protect lives and livelihoods, national security and the U.S. economy by providing timely, commonsense information, and rapidly identifying and responding to diseases, including outbreaks and illnesses. CDC drives science, public health research, and data innovation in communities across the country by investing in local initiatives to protect everyone’s health.\nAbout Harvard Pilgrim Health Care Institute’s Department of Population Medicine\nThe Harvard Pilgrim Health Care Institute's Department of Population Medicine is a unique collaboration between Harvard Pilgrim Health Care and Harvard Medical School. Created in 1992, it is the first appointing medical school department in the United States based in a health plan. The Institute focuses on improving health care delivery and population health through innovative research and education, in partnership with health plans, delivery systems, and public health agencies. Point32Health is the parent company of Harvard Pilgrim Health Care and Tufts Health Plan. Follow us on Twitter and LinkedIn.\nAbout HCA Healthcare\nNashville-based HCA Healthcare is one of the nation’s leading providers of healthcare services comprising 186 hospitals and approximately 2,400 ambulatory sites of care, including surgery centers, freestanding ERs, urgent care centers, and physician clinics, in 20 states and the United Kingdom. With its founding in 1968, HCA Healthcare created a new model for hospital care in the United States, using combined resources to strengthen hospitals, deliver patient-focused care and improve the practice of medicine. With a robust system for analyzing clinical data across large and diverse patient populations, HCA Healthcare is a leader in pragmatic research like the Swap Out, ABATE and REDUCE MRSA trials that can help identify new standards of care. HCA Healthcare is a learning health system that uses its more than 43 million annual patient encounters to advance science, improve patient care and save lives.\nAbout UCI Health\nUCI Health is the clinical enterprise of the University of California, Irvine, and the only academic health system in Orange County. Patients can access UCI Health at primary and specialty care offices across Orange County and at its main campus, UCI Medical Center in Orange, Calif. The 459-bed, acute care hospital, listed among America’s Best Hospitals by U.S. News & World Report for 22 consecutive years, provides tertiary and quaternary care, ambulatory and specialty medical clinics, behavioral health and rehabilitation services. UCI Medical Center is home to Orange County’s only National Cancer Institute-designated comprehensive cancer center, high-risk perinatal/neonatal program and American College of Surgeons-verified Level I adult and Level II pediatric trauma center and regional burn center. UCI Health serves a region of nearly 4 million people in Orange County, western Riverside County and southeast Los Angeles County. Follow us on Facebook, Instagram, LinkedIn and Twitter.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20240419656742/en/\nContacts\nHCA HEALTHCARE:Investor ContactFrank Morgan615-344-2688\nMedia ContactHarlow Sumerford615-344-1851\nHARVARD PILGRIM HEALTH CARE INSTITUTE: Maya Dutta-LinnMaya_Dutta-Linn@hphci.harvard.edu\nJessica MeulemanJessica_Meuleman@hphci.harvard.edu\nCENTERS FOR DISEASE CONTROL AND PREVENTION: Martha Sharan404-998-1787msharan@cdc.gov\nUCI HEALTH: Sophia Papa661-369-6968spapa@hs.uci.edu","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2428654986"}